A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae

Mario F. Feldman, Anne E. Mayer Bridwell, Nichollas E. Scott, Evgeny Vinogradov, Samuel R. McKee, Sthefany M. Chavez, Joy Twentyman, Christina L. Stallings, David A. Rosen, Christian M. Harding

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Hypervirulent Klebsiella pneumoniae (hvKp) is globally disseminating as a community-acquired pathogen causing life-threatening infections in healthy individuals. The fact that a dose as little as 50 bacteria is lethal to mice illustrates the dramatic increase of virulence associated with hvKp strains compared with classical K. pneumoniae (cKp) strains, which require lethal doses greater than 107 bacteria. Until recently, these virulent strains were mostly antibiotic-susceptible. However, multidrug-resistant (MDR) hvKp strains have been emerging, spawning a new generation of hypervirulent “superbugs.” The mechanisms of hypervirulence are not fully defined, but overproduction of capsular polysaccharide significantly impedes host clearance, resulting in increased pathogenicity of hvKp strains. While there are more than 80 serotypes of K. pneumoniae, the K1 and K2 serotypes cause the vast majority of hypervirulent infections. Therefore, a glycoconjugate vaccine targeting these 2 serotypes could significantly reduce hvKp infection. Conventionally, glycoconjugate vaccines are manufactured using intricate chemical methodologies to covalently attach purified polysaccharides to carrier proteins, which is widely considered to be technically challenging. Here we report on the recombinant production and analytical characterization of bioconjugate vaccines, enzymatically produced in glycoengineered Escherichia coli cells, against the 2 predominant hypervirulent K. pneumoniae serotypes, K1 and K2. The K. pneumoniae bioconjugates are immunogenic and efficacious, protecting mice against lethal infection from 2 hvKp strains, NTUH K-2044 and ATCC 43816. This preclinical study constitutes a key step toward preventing further global dissemination of hypervirulent MDR hvKp strains.

Original languageEnglish
Pages (from-to)18655-18663
Number of pages9
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number37
DOIs
StatePublished - Sep 10 2019

Keywords

  • Bioconjugation
  • Glycoconjugate
  • Hypervirulent Klebsiella pneumoniae
  • Vaccine

Fingerprint Dive into the research topics of 'A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae'. Together they form a unique fingerprint.

Cite this